Sex Differences in Psychotropic Drug Exposure and Safety: A Systematic Review Toward Personalized Dosing Strategies
Journal of Personalized Medicine · 31.03.2026 · 16 (4) · 189
DOI: 10.3390/jpm16040189 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 31.03.2026. Verfasst von Maria Puntarello und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Promotion, Mother and Childcare, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Piazza delle Clinic…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Biological sex contributes to variability in drug metabolism, receptor sensitivity, and susceptibility to adverse drug reactions (ADRs). Despite this, dosing recommendations for selective serotonin reuptake inhibitors (SSRIs) and second-generation antipsychotics (SGAs) are still largely sex-neutral. This systematic review examines sex-related differences in pharmacokinetics (PK), pharmacodynamics (PD), and safety outcomes, with the aim of clarifying their potential implications for personalized psychopharmacology.
Methods
A systematic search of PubMed was conducted for studies published between January 2010 and March 2026. The strategy combined MeSH terms and free-text keywords related to SSRIs, SGAs, sex differences, pharmacokinetics, pharmacodynamics, and ADRs. Two independent reviewers performed study selection and data extraction. Studies reporting sex-stratified PK, PD, or safety outcomes in humans were included. Owing to methodological heterogeneity, results were synthesized narratively.
Results
Twenty-seven studies met the inclusion criteria. Overall, the evidence indicates clinically meaningful sex-related differences in psychotropic drug exposure and response. Women more frequently exhibited higher dose-adjusted serum concentrations, particularly for risperidone and some SSRIs, with age-related increases more evident in females. Pharmacodynamic findings suggest that women may reach comparable dopamine D2 receptor occupancy at lower olanzapine doses. Pharmacovigilance analyses revealed sex-specific adverse event patterns, including greater reporting of endocrine-related effects and QT prolongation in women.
Conclusions
Sex influences psychotropic drug exposure, pharmacodynamic sensitivity, and safety profiles in ways that may be clinically relevant. Integrating sex-aware considerations into dosing strategies could improve therapeutic precision and reduce adverse outcomes, reinforcing the importance of sex as a key variable in personalized psychiatric care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Promotion, Mother and Childcare, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy.
ORCID-Profile: Maria Puntarello, Giuseppe Davide Albano, Stefania Zerbo, Ginevra Malta, Antonina Argo
Zitieren
APA
Puntarello, M., Albano, G. D., Zerbo, S., Malta, G., & Argo, A. (2026). Sex Differences in Psychotropic Drug Exposure and Safety: A Systematic Review Toward Personalized Dosing Strategies. Journal of Personalized Medicine, 16(4), 189. https://doi.org/10.3390/jpm16040189
Vancouver
Puntarello M, Albano GD, Zerbo S, Malta G, Argo A. Sex Differences in Psychotropic Drug Exposure and Safety: A Systematic Review Toward Personalized Dosing Strategies. Journal of Personalized Medicine. 2026;16(4):189. doi:10.3390/jpm16040189
BibTeX
@article{Puntarello2026,
author = {Puntarello, Maria and Albano, Giuseppe Davide and Zerbo, Stefania and Malta, Ginevra and Argo, Antonina},
title = {Sex Differences in Psychotropic Drug Exposure and Safety: A Systematic Review Toward Personalized Dosing Strategies},
journal = {Journal of Personalized Medicine},
year = {2026},
volume = {16},
number = {4},
pages = {189},
doi = {10.3390/jpm16040189}
}
EUVIMED